Acrivon Therapeutics, Inc. (ACRV): Capital Expenditures
$1.67M
Year ended 2025-12-31
$1.22M
Trailing 12 months to 2026-06-30
-8.3%
3-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.67M | -39.7% | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $2.77M | +114.9% | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | $1.29M | -40.5% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $2.17M | +810.1% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $238.0K | n/a | 2023-03-28, From 2021-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | 2025-12-31 | $1.67M | -39.7% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $55.0K | -73.9% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $567.0K | -89.1% |
| Seres Therapeutics, Inc. (MCRB) | 2025-12-31 | $252.0K | -33.7% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $925.6K | -43.0% |
| Kyntra Bio, Inc. (KYNB) | 2025-12-31 | $38.0K | -85.7% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $67.0K | -91.2% |
| Filana Therapeutics, Inc. (FLNA) | 2025-12-31 | $581.0K | +464.1% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $279.0K | -36.7% |
Compare ACRV, SLN, ZOMDF, MCRB side by side · Screen every company in Pharmaceutical Preparations ↗